Cynthia Xiuguang Ma MD Ph.D.

Breast Cancer, Hematologic Oncology

Professor, Internal Medicine, Washington University in St. Louis School of Medicine

4921 Parkview Pl# DvSt. Louis, MO 63110
Phone+1 800-647-2098
Fax+1 314-362-3192

Dr. Ma is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ma's full profile Already have an account?

Summary

Medical oncologist specializing in breast cancer and a physician-scientist experienced in clinical/translational research in the area of breast cancer biomarkers and molecular targeted treatment strategies.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2001 - 2005
Novant Health New Hanover Regional Medical CenterResidency, Internal Medicine, 1998 - 2001
University of CincinnatiPhD, Developmental Biology, 1997
Beijing Medical UniversityClass of 1990

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IL State Medical License 2020 - 2029
MO State Medical License 2005 - 2027
MN State Medical License 2001 - 2006
NC State Medical License 1998 - 2001
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification Follow My Health, Jardogs, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2014, 2016-2017

Clinical Trials

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
COMPLETED
PHASE1
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction
COMPLETED
PHASE2
PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer
TERMINATED
PHASE2

Publications & Presentations

PubMed

Cathepsin B-activated vitamin E prodrugs target cancer stem cells and enhance chemotherapy response in triple-negative breast cancer with minimal cardiotoxicity.
Raghu Pandurangi, Marco Tomasetti, Sekar T Verapazham, Ramasamy Paulmurugan, Cynthia Ma
Journal of Drug Targeting. 2026-08-10
SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.
François-Clement Bidard, Carlos Barrios, Giampaolo Bianchini, Adam M Brufsky, Stephen Chia
NPJ Breast Cancer. 2026-06-08
Circulating tumor DNA in breast cancer: updates from SABCS 2025.
Iris Zhi, Xianghui Zou, Min Sun, Nancy Chan, Naomi Ko
Journal of Hematology & Oncology. 2026-05-29

Journal Articles

Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer Xenografts
Souzan Sanati, Jana W Qiao, Xian Chen, Matthew J Ellis, Cynthia Ma, Nature

Other

Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy
Ma CX, Ellis M, Naughton MJ
http://www.uptodate.com/contents/treatment-approach-to-metastatic-hormone-receptor-positive-breast-c
UpToDate, Wolters Kluwer Health - 2013-01-16

Press Mentions

Tvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast CancerFebruary 23rd, 2023
Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient PopulationsJune 4th, 2021
Salvage Neoadjuvant Chemo Induces “Very Low” Pathologic Complete Response RateDecember 11th, 2020

Grant Support

Regulation of resistance to CDK4/6 inhibitor in breast cancerGEORGE WASHINGTON UNIVERSITY2023–2028
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancerWASHINGTON UNIVERSITY2022–2027
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancerWASHINGTON UNIVERSITY2022–2027
Washington University Co-Clinical Imaging Research ResourceWASHINGTON UNIVERSITY2017–2027
Washington University Co-Clinical Imaging Research ResourceWASHINGTON UNIVERSITY2017–2027

Committees

Member, Medical Oncologist Commimttee, ACOSOG 2009 - 2012
Member, Institutional Review Board of Human Research, Washington University 2006 - 2015
Member, CALGB Breast Cancer Committee 2006 - 2012

Research History

Principal InvestigatorPuma Biotechnology A Phase II Study of Neratinib in Metastatic HER2 Mutated Non-Amplified Breast Cancer.2013 - Present
Principal InvestigatorPfizer Pharmaceutical Inc. A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 inhibitor, in Combination with Anastrozole in Women with Clinical Stage II or III Estrogen Receptor Positive and HER2 Negative Breast Cancer.2013 - Present
Principal InvestigatorBreast Cancer Research Foundation The ALTERNATE Trial: A Biomarker Directed Approach in the management of postmenopausal women with linical stage II or III Estrogen Receptor Positive breast cancer.2016 - 2018
Principal InvestigatorEisai Pharmaceuticals Efficacy of Eribulin in Combination with Buparlisib in PDX models of TNBC2016 - 2018